Medicinal Chemistry Core

药物化学核心

• 批准号: 8655936
• 负责人: Joel Stephen Freundlich
• 金额: $ 50.63万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8655936
• 关键词: Academia; Address; Animal Testing; Anti-Bacterial Agents; Area; Bacterial Infections; Binding; Biological; Biological Assay; Chemicals; Chemistry; Clinical; Complement; Complex; Computer Simulation; Computing Methodologies; Consult; Cyclization; Data; Doctor of Philosophy; Drug Industry; Drug Kinetics; Enzymes; Evaluation; Evolution; Family; Foundations; Generations; Human Resources; Individual; Industry; Lead; Learning; Libraries; Metabolic; Methods; Mind; Mycobacterium tuberculosis; Paper; Peptides; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Plant Resins; Postdoctoral Fellow; Process; Program Research Project Grants; Property; RNA Polymerase Inhibitor; Research; Resources; S Phase; Scientist; Solid; Source; Structure; Techniques; Therapeutic; Time; Toxic effect; Translating; Translations; Validation; Vision; analog; chemical resource; cheminformatics; cost; design; drug candidate; drug discovery; experience; follow-up; global health; inhibitor/antagonist; insight; interest; member; novel; programs; screening; skills; small molecule; structural biology

The Medicinal Chemistry Core (MCC; Core D) will provide chemistry resources complementary to those existing within the respective project teams. The MCC resource will distinguish itself by relying on extensive pharmaceutical medicinal chemistry experience melded with an academic foundation in antibacterials. Critically, the MCC staff have demonstrated in the pharmaceutical industry setting their ability to discover drug candidates by evolving small molecules to address a wide range of problems encountered during the process. This experience will be essential to: Project 1) the optimization of small molecules ofthe arylpropionyl trialkylphloroglucinol family as antibacterials. Project 2) the evolution of small molecule inhibitors of essential metabolic enzymes, such Pks13, in M. tuberculosis. Project 4) the solid-phase synthesis of non-ribosomally encoded peptides with significant potential as antibacterials, and Project 5) the discovery and optimization of small molecule antibacterials leveraging Bayesian computational models. These projects necessitate experience with a diverse range of chemistries as found in the description of each MCC member's background. Overall, the spectrum and depth ofthe MCC staffs chemistry background will prove critical to their ability to translate basic scientific discoveries within the individual projects to small molecules with significant potential for positively impacting the antibacterial clinical landscape to address the global health crisis.

药物化学核心（MCC;核心D）将提供化学资源，以补充各自项目团队内的现有资源。MCC资源将通过依赖广泛的药物化学经验与抗菌药物的学术基础相结合而脱颖而出。至关重要的是，MCC的工作人员已经在制药行业中证明了他们通过发展小分子来解决过程中遇到的各种问题来发现候选药物的能力。这一经验将是必不可少的：项目1）优化小分子的芳基丙酰基三烷基间苯三酚家族作为抗菌剂。项目2）在M.结核项目4）具有显著抗菌潜力的非核糖体编码肽的固相合成，以及项目5）利用贝叶斯计算模型发现和优化小分子抗菌剂。这些项目需要具有各种化学品的经验，如在对每个MCC成员背景的描述中所述。总的来说，MCC员工的化学背景的广度和深度将被证明是至关重要的，他们能够将单个项目中的基础科学发现转化为小分子，这些小分子具有积极影响抗菌临床景观的巨大潜力，以解决全球健康危机。